Transaction #499 · Form 4 · 0001193125-25-240438
CRISPR Therapeutics AG · Exercise / conversion · Common Shares
CRISPR Therapeutics AG · Transacted October 13, 2025 · Filed October 15, 2025
What does this filing report?
An SEC Form 4 filing for CRISPR Therapeutics AG records an exercise / conversion involving Common Shares on October 13, 2025. The reported quantity was 8,334. The filing date is October 15, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- CRISPR Therapeutics AG
- Company CIK
- 0001674416
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 8,334
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 209,338
- Ownership description
- Not reported
- SEC acceptance time
- Oct 15, 2025, 5:35 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Kulkarni Samarth ↗
Chief Executive Officer · Director
CIK 0001682019
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- F2
- Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- F3
- This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.